Immune Pharmaceuticals Inc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Immune Pharmaceuticals Inc
Public Company Edition: The former Allergan CEO is taking a special purpose acquisition corporation public to generate $460m for deals in familiar biopharma niches. Also, IPOs are expected to keep up a robust pace in the fall and Albireo raises $160m on the success of its drug for pediatric liver diseases.
Qpex licenses rights to its antibiotic portfolio in China to Brii Biosciences. Moberg and DongKoo partner on commercialization of onychomycosis therapy in Korea.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Hanmi is reviewing a new global clinical trial plan for its novel lung cancer drug olmutinib after China's ZAI Lab returned its rights, and following Boehringer’s cancellation of a major-licensing deal in 2016. ZAI's decision may reflect the difficulties faced by olmutinib and other third generation EGFR inhibitors in competing with Tagrisso, as well as the increasingly crowded and rapidly changing non-small cell lung cancer space.
- Site Specific
- Topical Delivery
- Drug Delivery
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
- EpiCept Corporation (Maxim Pharmaceuticals)
- Cytovia, Inc.
- Immune Pharmaceuticals Ltd.